Srikripa Devarakonda
Stock Analyst at Truist Securities
(1.89)
# 3,126
Out of 4,910 analysts
63
Total ratings
33.9%
Success rate
-6.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Hold | $72 → $73 | $70.46 | +3.60% | 10 | May 27, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $7.89 | +39.42% | 1 | May 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $975 → $940 | $564.64 | +66.48% | 7 | Apr 30, 2025 | |
| BIIB Biogen | Maintains: Buy | $210 → $199 | $132.59 | +50.09% | 4 | Apr 29, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $43 → $25 | $14.38 | +73.85% | 5 | Apr 9, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $60 → $76 | $53.74 | +41.42% | 2 | Mar 11, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $805.43 | +28.88% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $190.83 | +13.71% | 3 | Feb 3, 2025 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $25.35 | +26.23% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $14.63 | +241.76% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $45 | $39.11 | +15.06% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 → $53 | $45.85 | +15.59% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.81 | +2,883.43% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $5.29 | +183.55% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $11.53 | +212.23% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $37.31 | +87.62% | 4 | May 29, 2024 |
Incyte
May 27, 2025
Maintains: Hold
Price Target: $72 → $73
Current: $70.46
Upside: +3.60%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $7.89
Upside: +39.42%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Buy
Price Target: $975 → $940
Current: $564.64
Upside: +66.48%
Biogen
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $132.59
Upside: +50.09%
Keros Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $14.38
Upside: +73.85%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $60 → $76
Current: $53.74
Upside: +41.42%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $805.43
Upside: +28.88%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $190.83
Upside: +13.71%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $25.35
Upside: +26.23%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $14.63
Upside: +241.76%
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $39.11
Upside: +15.06%
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $45.85
Upside: +15.59%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.81
Upside: +2,883.43%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $5.29
Upside: +183.55%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $11.53
Upside: +212.23%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $37.31
Upside: +87.62%